A Phase Ib/II Open Label Umbrella Study Evaluating Immunotherapy Based Combinations with Metastatic Pancreas Adenocarcinoma.
This study is a open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).